Download PDFPDF

EPV129/#529 Long-term clinical and economic value of pembrolizumab + lenvatinib compared with chemotherapy in previously treated advanced endometrial cancer patients in Sweden: a cost-effectiveness analysis
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address